1. Home
  2. GKOS vs CUZ Comparison

GKOS vs CUZ Comparison

Compare GKOS & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • CUZ
  • Stock Information
  • Founded
  • GKOS 1998
  • CUZ 1958
  • Country
  • GKOS United States
  • CUZ United States
  • Employees
  • GKOS N/A
  • CUZ N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • CUZ Real Estate Investment Trusts
  • Sector
  • GKOS Health Care
  • CUZ Real Estate
  • Exchange
  • GKOS Nasdaq
  • CUZ Nasdaq
  • Market Cap
  • GKOS 5.8B
  • CUZ 4.7B
  • IPO Year
  • GKOS 2015
  • CUZ N/A
  • Fundamental
  • Price
  • GKOS $94.32
  • CUZ $27.78
  • Analyst Decision
  • GKOS Strong Buy
  • CUZ Buy
  • Analyst Count
  • GKOS 12
  • CUZ 9
  • Target Price
  • GKOS $134.67
  • CUZ $32.11
  • AVG Volume (30 Days)
  • GKOS 869.3K
  • CUZ 1.6M
  • Earning Date
  • GKOS 07-30-2025
  • CUZ 07-31-2025
  • Dividend Yield
  • GKOS N/A
  • CUZ 4.61%
  • EPS Growth
  • GKOS N/A
  • CUZ N/A
  • EPS
  • GKOS N/A
  • CUZ 0.34
  • Revenue
  • GKOS $404,523,000.00
  • CUZ $892,818,000.00
  • Revenue This Year
  • GKOS $27.88
  • CUZ $13.20
  • Revenue Next Year
  • GKOS $27.60
  • CUZ $4.17
  • P/E Ratio
  • GKOS N/A
  • CUZ $81.95
  • Revenue Growth
  • GKOS 23.92
  • CUZ 10.04
  • 52 Week Low
  • GKOS $77.10
  • CUZ $24.07
  • 52 Week High
  • GKOS $163.71
  • CUZ $32.55
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 37.61
  • CUZ 33.69
  • Support Level
  • GKOS $92.42
  • CUZ $28.00
  • Resistance Level
  • GKOS $98.21
  • CUZ $28.77
  • Average True Range (ATR)
  • GKOS 2.85
  • CUZ 0.48
  • MACD
  • GKOS -1.10
  • CUZ -0.15
  • Stochastic Oscillator
  • GKOS 13.19
  • CUZ 13.35

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

Share on Social Networks: